Outlook Therapeutics, Inc. (OTLK): Cash & Equivalents
$8.08M
As of 2025-09-30
$11.24M
As of 2026-06-30
-22.5%
3-year compound annual growth
-8.4%
5-year compound annual growth
-1.1%
10-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-09-30 | $8.08M | -45.9% | 2025-12-19, Balance as of period end |
| 2024-09-30 | $14.93M | -36.2% | 2025-12-19, Balance as of period end |
| 2023-09-30 | $23.39M | +34.5% | 2024-12-27, Balance as of period end |
| 2022-09-30 | $17.40M | +20.2% | 2023-12-22, Balance as of period end |
| 2021-09-30 | $14.48M | +15.5% | 2022-12-29, Balance as of period end |
| 2020-09-30 | $12.54M | +56.4% | 2021-12-23, Balance as of period end |
| 2019-09-30 | $8.02M | +366.7% | 2020-12-23, Balance as of period end |
| 2018-09-30 | $1.72M | -46.1% | 2019-12-19, Balance as of period end |
| 2017-09-30 | $3.19M | +35.4% | 2018-12-18, Balance as of period end |
| 2016-09-30 | $2.35M | -74.1% | 2017-12-29, Balance as of period end |
| 2015-09-30 | $9.07M | n/a | 2016-12-29, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Outlook Therapeutics, Inc. (OTLK) | 2025-09-30 | $8.08M | -45.9% |
| Scinai Immunotherapeutics Ltd. (SCNI) | 2025-12-31 | $1.66M | -15.4% |
| Inhibrx Biosciences, Inc. (INBX) | 2025-12-31 | $124.22M | -18.6% |
| Pluri Inc. (PLUR) | 2026-06-30 | $3.53M | -40.1% |
| Humacyte, Inc. (HUMA) | 2025-12-31 | $50.50M | +12.4% |
| Aligos Therapeutics, Inc. (ALGS) | 2025-12-31 | $18.30M | -50.5% |
| Prokidney Corp. (PROK) | 2025-12-31 | $108.54M | +9.5% |
| ImageneBio, Inc. (IMA) | 2025-12-31 | $94.53M | +680.1% |
| Dyadic International Inc (DYAI) | 2025-12-31 | $4.62M | -29.0% |
Compare OTLK, SCNI, INBX, PLUR side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗